ARCT vs. NRIX, STOK, RCUS, LGND, STTK, ALKS, PRGO, CRNX, AXSM, and CORT
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Nurix Therapeutics (NRIX), Stoke Therapeutics (STOK), Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), Shattuck Labs (STTK), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
Arcturus Therapeutics (NASDAQ:ARCT) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Arcturus Therapeutics has a net margin of -81.59% compared to Nurix Therapeutics' net margin of -178.93%. Arcturus Therapeutics' return on equity of -37.61% beat Nurix Therapeutics' return on equity.
Arcturus Therapeutics has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
In the previous week, Arcturus Therapeutics had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 6 mentions for Nurix Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.99 beat Nurix Therapeutics' score of 0.75 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Arcturus Therapeutics has higher revenue and earnings than Nurix Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics received 378 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Nurix Therapeutics an outperform vote while only 65.44% of users gave Arcturus Therapeutics an outperform vote.
Arcturus Therapeutics presently has a consensus price target of $64.86, indicating a potential upside of 67.11%. Nurix Therapeutics has a consensus price target of $21.88, indicating a potential upside of 38.89%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Nurix Therapeutics.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. 13.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Arcturus Therapeutics beats Nurix Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
